Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles tagged with "Remission"

When Starting Biologics for RA, Disease Severity Predicts Likelihood of Remission

Reuters Staff  |  March 22, 2017

NEW YORK (Reuters Health)—After starting biologic therapy for rheumatoid arthritis (RA), patients with higher disease activity at baseline achieved greater improvements in measures of disease activity than those with lower levels of disease, but they were less likely to achieve remission or even low disease activity, according to a new real world analysis of registry data….

Methotrexate with Step-Down Glucocorticoid Remission Induction Works in Early RA

Reuters Staff  |  August 1, 2016

NEW YORK (Reuters Health)—Methotrexate with step-down glucocorticoid remission induction (COBRA Slim) is an effective, safe and feasible initial treatment strategy for patients with early rheumatoid arthritis (RA), researchers from Belgium report. Patients with early RA should be treated rapidly, intensively and to target, according to current guidelines, they note in a paper online July 18…

Remission of Rheumatoid Arthritis Tied to Lower Risk of Metabolic Syndrome

Reuters Staff  |  June 12, 2016

NEW YORK (Reuters Health)—Disease remission in patients with rheumatoid arthritis (RA) is associated with a lower risk of developing metabolic syndrome, according to a new study from Thailand. Researchers also found that a lower educational level was linked to a higher risk of metabolic syndrome, they report in Joint Bone Spine, online May 26. Dr….

Better Evidence Supports Slightly Revised Treat-to-Target Recommendations for RA

Will Boggs, MD  |  June 1, 2015

NEW YORK (Reuters Health)—A number of recent studies support last year’s update of 2010 treat-to-target recommendations for rheumatoid arthritis (RA), according to the international task force that revised them. Dr. Josef S. Smolen from Medical University of Vienna, Austria, and colleagues updated their 2010 advice based on systematic literature reviews and expert opinion. They left…

California Rheumatology Alliance 2013 Meeting: Aim for Remission in Rheumatoid Arthritis

Stephanie Cajigal  |  July 1, 2013

Early diagnosis and aggressive treatment of RA is key, expert says

New Criteria for RA Remission

David Holzman  |  February 12, 2011

ACR and EULAR update 1981 criteria to reflect modern treatment options

Pursue Remission

Carol A. Wallace, MD  |  November 1, 2007

Disease remission should be the goal for all rheumatologists treating childhood arthritis

Target Remission

Staff  |  March 1, 2007

Strategies to identify and track remission in your RA patients

  • « Previous Page
  • 1
  • 2
  • 3
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences